Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorized in the European Union In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild dementia due to Alzheimer’s disease (early AD) who are apolipoprotein E ε4 (ApoE ε4*) non-carriers or heterozygotes with confirmed amyloid pathology Lecanemab is the first therapy that targets an underlying cause of the disease to be authorized in the EU for eligible people with early AD TOKYO and CAMB...
Biogen’s Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer’s Disease CAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to BIIB080, an investigational antisense oligonucleotide (ASO) therapy targeting tau, for the treatment of Alzheimer’s disease. Fast Track designation is intended to facilitate the development and expedite the review of investigational drugs that treat serious conditions and address unmet...
Lonza Group AG / Key word(s): Miscellaneous Lonza Implements its Simplified and Streamlined Operating Model 01.04.2025 / 14:00 CET/CEST Lonza’s new simplified and streamlined operating model is designed to support its One Lonza vision and strategy Previous divisional structure is now replaced with three newly formed CDMO Business Platforms: Integrated Biologics, Advanced Synthesis, and Specialized Modalities The model comes into effect today, and is reflected on the updated website Basel, Switzerland, 1 April 2025 – Lonza has announced that its new simplified and streamlined o...
Lonza Group AG / Key word(s): Share Buyback Lonza Completes its Share Buyback Program 01.04.2025 / 07:00 CET/CEST Basel, Switzerland, 1 April 2025 – Lonza today announced the successful completion of its share buyback program of up to CHF 2 billion which was launched on 3 April 2023. Through the program, Lonza repurchased 4,239,731 of its shares on a second trading line on the SIX Swiss Exchange for an average purchase price of CHF 471.7279 per share.The Board of Directors intends to use the capital band to cancel the shares repurchased under the share buyback program. More informa...
Biogen Announces Plans for New Global Headquarters and Innovation Hub in Kendall Square Biogen signs lease for Kendall Common as part of multi-year real estate optimization plan to modernize its facilities and consolidate its Massachusetts real estate footprintNew building will be designed to foster collaboration and spark innovation; Biogen plans to relocate Cambridge-based employees to the new site in 2028 CAMBRIDGE, Mass., March 24, 2025 (GLOBE NEWSWIRE) -- Inc. (Nasdaq: BIIB) announced plans for its new global headquarters at Kendall Common, located at 75 Broadway in Cambridge...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.